Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

WHAT'S NEW

  • GLP-1s for Medicare
  • Drug Control Strategy
  • Misoprostol
  • AI Deepfakes
  • Fruit-Flavored Vapes

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Jun 27 2018

Full Issue

Much-Hyped Easy-To-Take Flu Drug Could Be Approved By FDA Before Next Season's Peak

People are buzzing about the single-dose drug that could revolutionize the way the flu is treated. Not only is it easy to take, but it's been shown to reduce the duration of flu symptoms by a little more than a day and reduce the duration of fever by nearly a day. In other public health news: contagious rudeness, osteoporosis, Zika, end-of-life care, and walking.

Stat: Flu Drug, Taken In Single Dose, Could Upend Treatment If Approved In U.S.

Next winter, there may be a new drug for people who contract influenza — one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single pill. The Food and Drug Administration on Tuesday said that it would give the drug, baloxavir morboxil, a priority review, and approval has the potential to upend the way influenza is treated. (Branswell, 6/27)

The Washington Post: Why Are We Being So Rude To Each Other? Research Shows Incivility Often Spreads Like A Contagious Cold

These are rude times we live in. And many people find themselves struggling with how to respond. Do they fight fire with fire or try somehow to take the moral high ground? Scientific research has surprisingly quite a lot to say about it all. (Wan, 6/26)

The Philadelphia Inquirer: Updated Osteoporosis Screening Guidelines Cover Only Women. That Could Hurt Men

The U.S. Preventive Services Task Force recommended, as it has for years, that women 65 and older and younger women with risk factors such as smoking be screened for osteoporosis with bone density scans, called DEXA. But not men. Even though the task force found “convincing evidence” that the scans detect osteoporosis and predict fractures in both men and women, it said there is “inadequate” evidence that treatment reduces fracture rates in men. (McCullough, 6/26)

The New York Times: High-Resolution Snapshot Of Zika Virus Reveals Clues To Fighting It

Scientists have captured the clearest and most detailed image yet of Zika, the virus that set off a global health crisis in 2015 and 2016 and left thousands of babies with serious birth defects. The work could contribute to the development of more effective vaccines and treatments to combat the virus. The research, published Tuesday in the journal Structure, combined tens of thousands of two-dimensional images to construct a three-dimensional model of the virus’s structure. (Baumgaertner, 6/26)

Los Angeles Times: Fewer Americans Are Spending Their Final Days In The Hospital And More Are Dying At Home

The American way of dying seems to have become less frantic, desperate and expensive. That’s the upshot of a new study that finds that seniors insured by Medicare who died in 2015 were less likely to do so in a hospital and more likely to pass away in a home or other community setting than those who died in 2000. The new research also showed that the proportion of American seniors who were admitted to the intensive care unit during their final month of life has stabilized after rising between 2000 and 2009. By 2015, 29% of dying patients insured by Medicare spent part of their final month of life in the ICU. (Healy, 6/27)

The New York Times: Walk Briskly For Your Health. About 100 Steps A Minute.

Most of us know that we should walk briskly for the sake of our health. But how fast is brisk? A helpful new study of walking speed and health concludes that the answer seems to be about 100 steps per minute, a number that is probably lower than many of us might expect. Current exercise guidelines almost always state that we should walk at a brisk pace rather than stroll leisurely. But the recommendations do not always define what brisk walking means and, when they do, can deploy daunting terminology or technicalities. (Reynolds, 6/27)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF